ASCO 2023 | Updates in the treatment of castration-resistant prostate cancer

Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, describes novel agents for the management of castration-resistant prostate cancer (CRPC), including an anti-PSCA CAR T-cell therapy, which was assessed in a Phase I trial (NCT03873805). Additional developments include a Phase I trial (NCT04886986) of 225Ac-J591, an alpha-radiolabeled antibody, and 177Lu-PSMA I&T, a beta-radioligand, in patients with metastatic CRPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.